Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Liabilities from Discontinued Operations (2017)

Summit Therapeutics filings provide 1 years of Liabilities from Discontinued Operations readings, the most recent being 2722.68 for Q4 2017.

  • Quarterly Liabilities from Discontinued Operations changed N/A to 2722.68 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 2722.68 through Dec 2017, changed N/A year-over-year, with the annual reading at 2722.68 for FY2017, N/A changed from the prior year.
  • Liabilities from Discontinued Operations hit 2722.68 in Q4 2017 for Summit Therapeutics, up from 10324000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 2722.68 in Q4 2017 and bottomed at 10324000.0 in Q2 2017.